Circassia Pharmaceuticals (CIRL)

 0.000p
   
  • Change Today:
      0.000p
  • 52 Week High: 0.000p
  • 52 Week Low: 0.000p
  • Currency: UK Pounds
  • Shares Issued: 284.89m
  • Volume: 0

Fundamentals - based on IFRS

  £ (Millions) £ (Millions) £ (Millions) £ (Millions) £ (Millions)
Income Statement 31-Dec-24 31-Dec-23 31-Dec-22 31-Dec-21 31-Dec-20
Continuing Operations          
Revenue 41.80 36.80 31.30 27.90 23.90
Operating Profit/(Loss) 7.70 4.60 1.80 (4.30) (17.30)
Profit Before Tax 7.80 4.10 10.50 (2.10) (18.40)
Profit After Tax 3.40 9.50 14.10 2.30 (26.80)
           
Earnings per Share - Basic 0.81p 2.26p 3.36p 0.55p (7.00p)
Earnings per Share - Adjusted 2.27p 3.87p 2.73p 0.55p (7.00p)
           
Dividend per Share n/a n/a n/a n/a n/a
  £ (Millions) £ (Millions) £ (Millions) £ (Millions) £ (Millions)
Balance Sheet 31-Dec-24 31-Dec-23 31-Dec-22 31-Dec-21 31-Dec-20
Assets          
Non-Current Assets          
Property, Plant & Equipment 1.70 1.40 1.10 1.40 1.40
Intangible Assets 27.80 32.80 37.10 42.10 50.40
Other Non-Current Assets 17.80 23.80 28.90 23.10 21.60
  47.30 58.00 67.10 66.60 73.40
Current Assets          
Inventories 4.00 4.80 4.10 2.70 4.00
Cash at Bank & in Hand 10.90 19.90 19.40 12.60 7.40
Other Current Assets n/a n/a n/a n/a n/a
  21.10 33.50 31.40 19.80 29.70
           
Other Assets n/a n/a n/a n/a n/a
Total Assets 68.40 91.50 98.50 86.40 103.10
Current Liabilities          
Borrowings 0.70 0.60 0.60 0.40 0.80
Other Current Liabilities 7.40 6.60 8.60 10.40 25.90
           
Current Liabilities 8.10 7.20 9.20 10.80 26.70
           
Net Current Assets cn/a cn/a cn/a cn/a cn/a
           
Borrowings 0.80 0.50 0.40 0.90 0.80
Other Non-Current Liabilities n/a n/a n/a n/a n/a
Non-Current Liabilities 0.80 0.50 7.40 8.80 10.30
           
Other Liabilities n/a n/a n/a n/a n/a
Total Liabilities 8.90 7.70 16.60 19.60 37.00
           
Net Assets 59.50 83.80 81.90 66.80 66.10
           
Shareholders Funds 59.50 83.80 81.90 66.80 66.10
           
Minority Interests/Other Equity n/a n/a n/a n/a n/a
Total Equity 59.50 83.80 81.90 66.80 66.10
Cash Flow 31-Dec-24 31-Dec-23 31-Dec-22 31-Dec-21 31-Dec-20
Net Cash Flow From Operating Activities 17.20 11.60 6.70 1.40 (23.90)
Net Cash Flow from Investing Activities (1.00) (0.30) (0.10) (0.20) (0.50)
Net Cash Flow from Financing Activities (25.10) (10.50) (0.50) 4.10 4.30
Net Increase/Decrease In Cash (8.90) 0.80 6.10 5.30 (20.10)
Ratios - based on IFRS 31-Dec-24 31-Dec-23 31-Dec-22 31-Dec-21 31-Dec-20
Continuing Operations          
PE Ratio - Adjusted n/a n/a n/a 71.1 n/a
PEG - Adjusted n/a n/a n/a n/a n/a
Earnings per Share Growth - Adjusted -41% 42% 396% n/a n/a
Dividend Cover n/a n/a n/a n/a n/a
Revenue per Share 14.67p 12.92p 10.99p 0.099p 8.39p
Pre-Tax Profit per Share 2.74p 1.44p 3.69p 0.007p (6.46p)
Operating Margin 18.42% 12.50% 5.75% (15.41%) (72.38%)
Return on Capital Employed 21.39% 6.72% 19.89% n/a n/a
           
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0%
Dividend per Share Growth n/a n/a n/a n/a n/a
Operating Cash Flow per Share 6.04p 4.07p 2.35p 0.49p (8.39p)
Cash Incr/Decr per Share (3.12p) 0.28p 2.14p 0.019p (7.05p)
Net Asset Value per Share (exc. Intangibles) 11.13p 17.90p 15.72p 8.67p 5.51p
Net Gearing -15.80% -22.43% -22.47% -16.92% -8.77%

Key

* GAAP

a. Includes discontinued activities

b. Including assets due in more than one year

c. Not disclosed under IFRS

d. Total fixed assets

e. Includes borrowings

f. Included in cash flow from operating activities under IFRS

g. Included in net cash from investing activities under IFRS

h. Pre-tax

i. Capital expenditure

j. Based on operating cash flow before tax

k. Issue of ordinary shares

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 5 minutes.

Note 2: Forecast figures based on normalised accounts.

 

Top of Page